Literature DB >> 45788

Quantitative comparisons of various biological responses of neutrophils to different active and inactive chemotactic factors.

D L Kreutzer1, J T O'Flaherty, W Orr, H J Showell, P A Ward, E L Becker.   

Abstract

The effects of chemotactic factors on rabbit neutrophils were evaluated measuring cell migration in modified Boyden chambers and under agarose, in lysosomal enzyme release, leukocyte aggregation, and in vivo neutropenia. Chemotactins employed included the complement-derived C3 and C5 fragments, the bacterial chemotactic factor from culture supernatant fluids of Escherichia coli, and the synthetic chemotactic factors Met-Leu-Phe and formyl-Met-Leu-Phe. A consistent parallelism was found in all the leukocyte responses to a given chemotactic factor. In no instance, with any of the five chemotactic factor preparations, did cells responding in one assay system fail to respond in the four other assay systems, suggesting a common event in all of the cell responses. Boyden chamber chemotaxis was consistently the most sensitive assay; the agarose assay was, in general, less sensitive by a factor of 100 fold. Enzyme release approached, in cell sensitivity to chemotactic factors, that of the Boyden chamber assay. In general, in vitro leukocyte aggregation and in vivo neutropenia were considerably less sensitive assays. Chemotactic factor inactivator (CFI) purified from human serum destroyed in parallel all biological activities of C3 and C5 chemotactic factors but had no effect on the bacterial chemotactic factor and the activities of synthetic chemotactic peptides.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 45788     DOI: 10.1016/0162-3109(78)90007-3

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  20 in total

Review 1.  In vitro assays of angiogenesis for assessment of angiogenic and anti-angiogenic agents.

Authors:  Anne M Goodwin
Journal:  Microvasc Res       Date:  2007-06-06       Impact factor: 3.514

2.  The dependence on Ca2+ of the guanine-nucleotide-activated polyphosphoinositide phosphodiesterase in neutrophil plasma membranes.

Authors:  S Cockcroft
Journal:  Biochem J       Date:  1986-12-01       Impact factor: 3.857

3.  Pentoxifylline-induced modulation of human leukocyte function in vitro.

Authors:  K Josaki; J Contrino; J Kristie; P Krause; D L Kreutzer
Journal:  Am J Pathol       Date:  1990-03       Impact factor: 4.307

4.  Acute inflammatory pulmonary reactions induced by chemotactic factors.

Authors:  U Desai; D L Kreutzer; H Showell; C V Arroyave; P A Ward
Journal:  Am J Pathol       Date:  1979-07       Impact factor: 4.307

5.  Polymorphonuclear leucocyte function and previous yersinia arthritis: correlation of enhanced superoxide production with late manifestations.

Authors:  H Repo; P Koivuranta-Vaara; M Leirisalo-Repo
Journal:  Ann Rheum Dis       Date:  1988-06       Impact factor: 19.103

6.  The chemotactic response of tumor cells. A model for cancer metastasis.

Authors:  W C Lam; E J Delikatny; F W Orr; J Wass; J Varani; P A Ward
Journal:  Am J Pathol       Date:  1981-07       Impact factor: 4.307

7.  Receptor blockade as a mechanism of deactivation of human neutrophils by pepstatin and formyl-Met-Leu-Phe.

Authors:  I Spilberg; J Mehta; M A Muniain; L Simchowitz; J Atkinson
Journal:  Inflammation       Date:  1984-03       Impact factor: 4.092

8.  Comparison of adhesion to glass and aggregation of human leucocytes.

Authors:  B Damerau; H U Keller
Journal:  Agents Actions       Date:  1983-02

9.  Pentoxifylline enhancement of defective neutrophil function and host defense in neonatal mice.

Authors:  P J Krause; J Kristie; W P Wang; L Eisenfeld; V C Herson; E G Maderazo; K Jozaki; D L Kreutzer
Journal:  Am J Pathol       Date:  1987-11       Impact factor: 4.307

10.  Characterization of neutrophil and monocyte specific chemotactic factors derived from the cornea in response to hydrogen peroxide injury.

Authors:  S A Elgebaly; N Herkert; J O'Rourke; D L Kreutzer
Journal:  Am J Pathol       Date:  1987-01       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.